canertinib and Acute Myelogenous Leukemia
canertinib has been researched along with Acute Myelogenous Leukemia in 3 studies
Research
Studies (3)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Djerf, EA; Hallbeck, AL; Jönsson, JI; Trinks, C; Walz, TM | 1 |
Druid, P; Eliasson, P; Gréen, H; Jönsson, JI; Lotfi, K; Nordigården, A; Rönnstrand, L; Trinks, C; Walz, TM; Zetterblad, J | 1 |
Other Studies
3 other study(ies) available for canertinib and Acute Myelogenous Leukemia
Article | Year |
---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells.
Topics: Antineoplastic Agents; Apoptosis; G1 Phase; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Morpholines; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2010 |
Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
Topics: Animals; Apoptosis; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred DBA; Morpholines; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Oncogene Proteins v-erbB; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Signal Transduction; Tandem Repeat Sequences; Tumor Cells, Cultured | 2011 |